** Shares of Australia's Alterity Therapeutics ATH.AX fall as much as 8.3% to A$0.011, on track for a third consecutive session of decline
** Stock hits its lowest level since Jan. 31
** Biotechnology co raises A$40.0 mln ($25.02 mln) in a placement at an issue price of A$0.011 per share
** Issue price represents a discount of 8.3% to stock's last close
** Co says funds will be used primarily to advance development of ATH434, a small molecule drug candidate for Parkinsonian disorders
** Stock up 43.8% this year, as of 0159 GMT
($1 = 1.5990 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。